Trial Profile
An Observational Retrospective Database Analysis to Estimate the Risk of Multiple Sclerosis Following Vaccination With Arepanrix in Manitoba, Canada
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Aug 2023
Price :
$35
*
At a glance
- Drugs Influenza A virus H1N1 vaccines (Primary)
- Indications Influenza A virus H1N1 subtype
- Focus Adverse reactions
- Acronyms H1N1-014VS
- 10 May 2016 Status changed from active, no longer recruiting to completed.
- 25 Feb 2015 New trial record